Enhancing the antidepressant effects of scopolamine through mGlu2 receptor antagonism as an emerging approach for treating depression
Pharmacological Reports · 16.11.2026
DOI: 10.1007/s43440-026-00928-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reports, online erschienen am 16.11.2026. Verfasst von Yana Babii und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This research was funded by the National Science Centre, Poland,.
Themen: Depression
Abstract (Originalsprache)
Conventional antidepressants remain not effective enough to treat depression, with only 30–40% of patients achieving full remission. This has intensified the call for a deeper understanding of depression’s biological mechanisms, moving beyond the traditional monoaminergic hypothesis. The cholinergic hypothesis, first proposed in the 1970s, has gained renewed interest due to the rapid antidepressant effects of scopolamine, a muscarinic receptor antagonist. Despite its potential, scopolamine’s side effects hinder clinical use. Recent research highlights dysregulation of glutamatergic neurotransmission in depression, and targeting metabotropic glutamate (mGlu) receptors presents a novel therapeutic strategy. Evidence suggests that mGlu_2 receptors play a critical role in the rapid antidepressant effect, and mGlu_2 receptor antagonists possess antidepressant-like potential in animal models of depression. Importantly, mGlu_2 antagonists such as LY341495 or the mGlu_2 negative allosteric modulator VU6001966, when coadministered with scopolamine, enhance scopolamine’s antidepressant efficacy while reducing cognitive side effects. Data indicate that ligands of other mGlu receptor subtypes, including group III mGlu receptors, may also enhance the therapeutic effects of scopolamine while avoiding undesirable effects. This review study underscores the urgent need for innovative approaches to depression treatment, emphasizing the importance of mGlu_2 as a promising target for future therapeutic development, especially as co-treatment with low doses of scopolamine. The mechanism related to the potentiation of the antidepressant effect of scopolamine by VU6001966, including activation of AMPA receptors and BDNF–TrkB signaling, is also discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland.
- Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, Kraków, 31-343, Poland. andrzej.pilc@if-pan.edu.pl.
Förderung
- This research was funded by the National Science Centre, Poland,
Zitieren
APA
Babii, Y., Pałucha-Poniewiera, A., & Pilc, A. (2026). Enhancing the antidepressant effects of scopolamine through mGlu2 receptor antagonism as an emerging approach for treating depression. Pharmacological Reports. https://doi.org/10.1007/s43440-026-00928-5
Vancouver
Babii Y, Pałucha-Poniewiera A, Pilc A. Enhancing the antidepressant effects of scopolamine through mGlu2 receptor antagonism as an emerging approach for treating depression. Pharmacological Reports. 2026. doi:10.1007/s43440-026-00928-5
BibTeX
@article{Babii2026,
author = {Babii, Yana and Pałucha-Poniewiera, Agnieszka and Pilc, Andrzej},
title = {Enhancing the antidepressant effects of scopolamine through mGlu2 receptor antagonism as an emerging approach for treating depression},
journal = {Pharmacological Reports},
year = {2026},
doi = {10.1007/s43440-026-00928-5}
}
EUVIMED